Current perspective on rituximab in rheumatic diseases

References

• DornerTBurmesterGRThe role of B cells in rheumatoid arthritis: mechanisms and therapeutic targetsCurr Opin Rheumatol2003153 246 25212707577
   PubMed Web of Science ®Google Scholar
• OlsenNJSteinCMNew drugs for rheumatoid arthritisN Engl J Med200435021 2167 217915152062
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration [webpage on the Internet]Questions and Answers on Rituximab (added 12/19/2006) Available from: https://wayback.archive-it.org/7993/20170722191606/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109107.htmAccessed August 9, 2017
   Google Scholar
• EdwardsJCSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med200435025 2572 258115201414
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRFilipowicz-SosnowskaAThe efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialArthritis Rheum2006545 1390 140016649186
   PubMed Web of Science ®Google Scholar
• Rubbert-RothATakPPZerbiniCEfficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)Rheumatology2010499 1683 169320463186
   PubMed Web of Science ®Google Scholar
• EmeryPDeodharARigbyWFEfficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE))Ann Rheum Dis2010699 1629 163520488885
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum2006549 2793 280616947627
   PubMed Web of Science ®Google Scholar
• CohenSBKeystoneEGenoveseMCContinued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateAnn Rheum Dis2010696 1158 116120439295
   PubMed Web of Science ®Google Scholar
• MeasePJCohenSGaylisNBEfficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trialJ Rheumatol2010375 917 92720194448
   PubMed Web of Science ®Google Scholar
• HaraouiBBokarewaMKallmeyerIBykerkVPInvestigatorsRSafety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET TrialJ Rheumatol20113812 2548 255621965646
   PubMed Web of Science ®Google Scholar
• EmeryPGottenbergJERubbert-RothARituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyAnn Rheum Dis2015746 979 98424442884
   PubMed Web of Science ®Google Scholar
• IngegnoliFCastelliRGualtierottiRRheumatoid factors: clinical applicationsDis Markers2013356 727 73424324289
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJManeiroJRRuizJComparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR StudyAnn Rheum Dis20127111 1861 186422736086
   PubMed Web of Science ®Google Scholar
• IngegnoliFFavalliEGMeroniPLDoes polymorphism of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literatureAutoimmun Rev2011108 460 46321296193
   PubMed Web of Science ®Google Scholar
• TakPPRigbyWFRubbert-RothAInhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trialAnn Rheum Dis2011701 39 4620937671
   PubMed Web of Science ®Google Scholar
• TakPPRigbyWRubbert-RothASustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGEAnn Rheum Dis2012713 351 35722012969
   PubMed Web of Science ®Google Scholar
• MokCCRituximab for the treatment of rheumatoid arthritis: an updateDrug Des Devel Ther20138 87 100
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJBaconPA2012 revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis Rheum2013651 1 1123045170
   PubMed Web of Science ®Google Scholar
• KeoghKALimperAHCharacterization of lymphocyte populations in nonspecific interstitial pneumoniaRespir Res20056 13716287509
   PubMed Web of Science ®Google Scholar
• KeoghKAYtterbergSRFervenzaFCCarlsonKASchroederDRSpecksURituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trialAm J Respir Crit Care Med20061732 180 18716224107
   PubMed Web of Science ®Google Scholar
• StoneJHMerkelPASpieraRRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med20103633 221 23220647199
   PubMed Web of Science ®Google Scholar
• SpecksUMerkelPASeoPEfficacy of remission-induction regimens for ANCA-associated vasculitisN Engl J Med20133695 417 42723902481
   PubMed Web of Science ®Google Scholar
• FussnerLAHummelAMSchroederDRFactors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3Arthritis Rheumatol2016687 1700 171026882078
   PubMed Web of Science ®Google Scholar
• GuillevinLPagnouxCKarrasARituximab versus azathioprine for maintenance in ANCA-associated vasculitisN Engl J Med201437119 1771 178025372085
   PubMed Web of Science ®Google Scholar
• GopaluniSSmithRMLewinMRituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trialTrials2017181 11228270229
   PubMed Web of Science ®Google Scholar
• SanzILeeFEB cells as therapeutic targets in SLENat Rev Rheumatol201066 326 33720520647
   PubMed Web of Science ®Google Scholar
• LeandroMJCambridgeGEdwardsJCEhrensteinMRIsenbergDAB-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patientsRheumatology20054412 1542 154516188950
   PubMed Web of Science ®Google Scholar
• LuTYNgKPCambridgeGA retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patientsArthritis Rheum2009614 482 48719333973
   PubMed Web of Science ®Google Scholar
• Diaz-LagaresCCrocaSSangleSEfficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohortsAutoimmun Rev2012115 357 36422032879
   PubMed Web of Science ®Google Scholar
• LightstoneLThe landscape after LUNAR: rituximab’s crater-filled pathArthritis Rheum2012644 962 96522231618
   PubMed Web of Science ®Google Scholar
• CondonMBAshbyDPepperRJProspective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnn Rheum Dis2013728 1280 128623740227
   PubMed Web of Science ®Google Scholar
• WittMGrunkeMProftFClinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)Lupus20132211 1142 114924057058
   PubMed Web of Science ®Google Scholar
• WilhelmusSBajemaIMBertsiasGKLupus nephritis management guidelines comparedNephrol Dial Transplant2016316 904 91325920920
   PubMed Web of Science ®Google Scholar
• MerrillJTNeuweltCMWallaceDJEfficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialArthritis Rheum2010621 222 23320039413
   PubMed Web of Science ®Google Scholar
• RovinBHFurieRLatinisKEfficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studyArthritis Rheum2012644 1215 122622231479
   PubMed Web of Science ®Google Scholar
• AlbertDDunhamJKhanSVariability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnn Rheum Dis20086712 1724 173118250115
   PubMed Web of Science ®Google Scholar
• LindholmCBorjesson-AspKZendjanchiKSundqvistACTarkowskiABokarewaMLongterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosusJ Rheumatol2008355 826 83318398943
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMGarcia-HernandezFJde RamonEOff-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseasesClin Exp Rheumatol2010284 468 47620525449
   PubMed Web of Science ®Google Scholar
• VitalEMDassSBuchMHB cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis Rheum20116310 3038 304721618204
   PubMed Web of Science ®Google Scholar
• Fernandez-NebroAde la FuenteJLCarrenoLMulticenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB studyLupus20122110 1063 107622786985
   PubMed Web of Science ®Google Scholar
• TerrierBAmouraZRavaudPSafety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryArthritis Rheum2010628 2458 246620506527
   PubMed Web of Science ®Google Scholar
• WangCRLiuMFRituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experienceSemin Arthritis Rheum2016461 102 10826992634
   PubMed Web of Science ®Google Scholar
• TokunagaMSaitoKKawabataDEfficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous systemAnn Rheum Dis2007664 470 47517107983
   PubMed Web of Science ®Google Scholar
• PintoLFVelasquezCJPrietoCMestraLForeroEMarquezJDRituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosusLupus20112011 1219 122621784778
   PubMed Web of Science ®Google Scholar
• KotagiriPMartinAHughesPBeckerGNichollsKSingle-dose rituximab in refractory lupus nephritisIntern Med J2016468 899 90127242250
   PubMed Web of Science ®Google Scholar
• SimonettaFAllaliDRoux-LombardPChizzoliniCSuccessful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumabJoint Bone Spine2016842 235 23627238199
   PubMed Web of Science ®Google Scholar
• Ryden-AulinMBoumpasDBultinkIOff-label use of rituximab for systemic lupus erythematosus in EuropeLupus Sci Med201631 e00016327651920
   PubMedGoogle Scholar
• CornecDDevauchelle-PensecVTobonGJPersJOJousse-JoulinSSarauxAB cells in Sjogren’s syndrome: from pathophysiology to diagnosis and treatmentJ Autoimmun2012393 161 16722749831
   PubMed Web of Science ®Google Scholar
• DassSBowmanSJVitalEMReduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot studyAnn Rheum Dis20086711 1541 154418276741
   PubMed Web of Science ®Google Scholar
• MeijerJMMeinersPMVissinkAEffectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trialArthritis Rheum2010624 960 96820131246
   PubMed Web of Science ®Google Scholar
• Devauchelle-PensecVMarietteXJousse-JoulinSTreatment of primary Sjogren syndrome with rituximab: a randomized trialAnn Intern Med20141604 233 24224727841
   PubMed Web of Science ®Google Scholar
• SouzaFBPorfirioGJAndrioloBNAlbuquerqueJVTrevisaniVFRituximab effectiveness and safety for treating primary Sjogren’s syndrome (pSS): systematic review and meta-analysisPLoS One2016113 e015074926998607
   PubMed Web of Science ®Google Scholar
• CarubbiFCiprianiPMarrelliAEfficacy and safety of rituximab treatment in early primary Sjogren’s syndrome: a prospective, multi-center, follow-up studyArthritis Res Ther2013155 R17224286296
   PubMed Web of Science ®Google Scholar
• CornecDDevauchelle-PensecVMarietteXDevelopment of the Sjogren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacyRheumatology2015549 1699 170825957440
   PubMed Web of Science ®Google Scholar
• Jousse-JoulinSDevauchelle-PensecVCornecDBrief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren’s syndromeArthritis Rheumatol2015676 1623 162825708147
   PubMed Web of Science ®Google Scholar
• CarsonsSEVivinoFBParkeATreatment guidelines for rheumatologic manifestations of Sjogren’s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal painArthritis Care Res2016694 517 527
   Web of Science ®Google Scholar
• De VitaSQuartuccioLSalvinSSequential therapy with belimumab followed by rituximab in Sjogren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacyClin Exp Rheumatol2014324 490 49424802131
   PubMed Web of Science ®Google Scholar
• MarietteXSerorRQuartuccioLEfficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II studyAnn Rheum Dis2015743 526 53124347569
   PubMed Web of Science ®Google Scholar
• ChenMHChenCKChouHPChenMHTsaiCYChangDMRituximab therapy in primary Sjogren’s syndrome with interstitial lung disease: a retrospective cohort studyClin Exp Rheumatol2016346 1077 108427607895
   PubMed Web of Science ®Google Scholar
• GottenbergJECinquettiGLarrocheCEfficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registryAnn Rheum Dis2013726 1026 103123264337
   PubMed Web of Science ®Google Scholar
• MeinersPMArendsSMeijerJMEfficacy of retreatment with rituximab in patients with primary Sjogren’s syndromeClin Exp Rheumatol2015333 443 44425897541
   PubMed Web of Science ®Google Scholar
• CornecDCostaSDevauchelle-PensecVBlood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren’s syndromeJ Autoimmun201667 102 11026688003
   PubMed Web of Science ®Google Scholar
• DelliKHaackeEAKroeseFGTowards personalised treatment in primary Sjogren’s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatmentAnn Rheum Dis20167511 1933 193826757748
   PubMed Web of Science ®Google Scholar
• FoxRIFoxCMSjogren syndrome: why do clinical trials fail?Rheum Dis Clin North Am2016423 519 53027431352
   PubMed Web of Science ®Google Scholar
• BoselloSDe LucaGTolussoBB cells in systemic sclerosis: a possible target for therapyAutoimmun Rev20111010 624 63021545850
   PubMed Web of Science ®Google Scholar
• IngegnoliFTrabattoniDSaresellaMFantiniFClericiMDistinct immune profiles characterize patients with diffuse or limited systemic sclerosisClin Immunol20031081 21 2812865067
   PubMed Web of Science ®Google Scholar
• IngegnoliFGualtierottiRSchioppoTFibrosis biomarkers in isolated Raynaud’s phenomenon: too little, too soon?Ann Rheum Dis2014735 940 94124344159
   PubMed Web of Science ®Google Scholar
• OkamotoMOkanoAAkamatsuSRituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host diseaseLeukemia2006201 172 17316239908
   PubMed Web of Science ®Google Scholar
• McGonagleDTanALMaddenJSuccessful treatment of resistant scleroderma-associated interstitial lung disease with rituximabRheumatology2008474 552 55318281368
   PubMed Web of Science ®Google Scholar
• LafyatisRKissinEYorkMB cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis Rheum2009602 578 58319180481
   PubMed Web of Science ®Google Scholar
• BoselloSDe SantisMLamaGB cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trialArthritis Res Ther2010122 R5420338043
   PubMed Web of Science ®Google Scholar
• DaoussisDLiossisSNTsamandasACEffect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosisClin Exp Rheumatol2012302 suppl 71 S17 S2222244622
   PubMed Web of Science ®Google Scholar
• SmithVVan PraetJTVandoorenBRituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological studyAnn Rheum Dis2010691 193 19719103636
   PubMed Web of Science ®Google Scholar
• SmithVPietteYvan PraetJTTwo-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvementJ Rheumatol2013401 52 5723118116
   PubMed Web of Science ®Google Scholar
• Moazedi-FuerstFCKielhauserSMBrickmannKRituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimenScand J Rheumatol2014433 257 25824611681
   PubMed Web of Science ®Google Scholar
• GiuggioliDLumettiFColaciMFallahiPAntonelliAFerriCRituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literatureAutoimmun Rev20151411 1072 107826209905
   PubMed Web of Science ®Google Scholar
• DaoussisDLiossisSNTsamandasACExperience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyRheumatology2010492 271 28019447770
   PubMed Web of Science ®Google Scholar
• GualtierottiRIngegnoliFScaloneLFeasibility, acceptability and construct validity of EQ-5D in systemic sclerosisSwiss Med Wkly2017146 w1439428102877
   PubMed Web of Science ®Google Scholar
• GhrenassiaEAvouacJKhannaDPrevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control studyJ Rheumatol2014411 99 10524293584
   PubMed Web of Science ®Google Scholar
• JordanSDistlerJHMaurerBEffects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) groupAnn Rheum Dis2015746 1188 119424442885
   PubMed Web of Science ®Google Scholar
• BoselloSLDe LucaGRuccoMLong-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosisSemin Arthritis Rheum2015444 428 43625300701
   PubMed Web of Science ®Google Scholar
• DaoussisDMelissaropoulosKSakellaropoulosGA multi-center, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung diseaseSemin Arthritis Rheum2016465 625 63127839742
   PubMed Web of Science ®Google Scholar
• SongIHHeldmannFRudwaleitMDifferent response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trialArthritis Rheum2010625 1290 129720461780
   PubMed Web of Science ®Google Scholar
• SongIHHeldmannFRudwaleitMOne-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flareAnn Rheum Dis2013722 305 30622887847
   PubMed Web of Science ®Google Scholar
• GordonPAWinerJBHoogendijkJEChoyEHImmunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositisCochrane Database Syst Rev20128 CD00364322895935
   PubMed Web of Science ®Google Scholar
• ShinjoSKde SouzaFHde MoraesJCDermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics)Rev Bras Reumatol2013531 101 11023588520
   PubMedGoogle Scholar
• OddisCVReedAMAggarwalRRituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trialArthritis Rheum2013652 314 32423124935
   PubMed Web of Science ®Google Scholar
• AggarwalRLoganathanPKoontzDQiZReedAMOddisCVCutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximabRheumatology2017562 247 25427837048
   PubMed Web of Science ®Google Scholar
• LambotteOKotbRMaigneGBlancFXGoujardCDelfraissyJFEfficacy of rituximab in refractory polymyositisJ Rheumatol2005327 1369 137015996082
   PubMed Web of Science ®Google Scholar
• MarieIDominiqueSJanvresseALevesqueHMenardJFRituximab therapy for refractory interstitial lung disease related to antisynthetase syndromeRespir Med20121064 581 58722280877
   PubMed Web of Science ®Google Scholar
• RiderLGYipALHorkayne-SzakalyINovel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trialClin Exp Rheumatol2014325 689 69625068290
   PubMed Web of Science ®Google Scholar
• AnderssonHSemMLundMBLong-term experience with rituximab in anti-synthetase syndrome-related interstitial lung diseaseRheumatology2015548 1420 142825740830
   PubMed Web of Science ®Google Scholar
• MahlerEABlomMVoermansNCvan EngelenBGvan RielPLVonkMCRituximab treatment in patients with refractory inflammatory myopathiesRheumatology20115012 2206 221321571768
   PubMed Web of Science ®Google Scholar
• ReedAMCrowsonCSHeinMBiologic predictors of clinical improvement in rituximab-treated refractory myositisBMC Musculoskelet Disord201516 25726382217
   PubMed Web of Science ®Google Scholar
• AggarwalROddisCVGoudeauDAutoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRheumatology2016556 991 99926888854
   PubMed Web of Science ®Google Scholar
• YooDHSuhCHShimSCA multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritisAnn Rheum Dis2017763 566 57027624791
   PubMed Web of Science ®Google Scholar
• YooDHParkWSuhCH webpage on the InternetEfficacy and safety of switched CT-10 from innovator rituximab compared to those of maintained CT-10 in patients with rheumatoid arthritis up to 56 weeksArthritis Rheumatol201567suppl 10 Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-switched-ct-p10-from-innovator-rituximab-compared-to-those-of-maintained-ct-p10-in-patients-with-rheumatoid-arthritis-up-to-56-weeks/Accessed July 20, 2017
   Google Scholar
• SmolenJScheinbergMTonyHFRI0222 pharmacokinetics, pharmacodynamics, safety and efficacy of proposed rituximab biosimilar (GP2013) vs EU-approved rituximab (RTX) in patients with rheumatoid arthritis: results from a randomized controlled trial (GP13-201) over 52 weeksAnn Rheum Dis201675 512 513
   Web of Science ®Google Scholar
• CohenSEmeryPGreenwaldMA phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritisBr J Clin Pharmacol2016821 129 13826909489
   PubMed Web of Science ®Google Scholar
• DornerTStrandVCornesPThe changing landscape of biosimilars in rheumatologyAnn Rheum Dis2016756 974 98226964144
   PubMed Web of Science ®Google Scholar
• SchroderCAzimzadehAMWuGPriceJOAtkinsonJBPiersonRNAnti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTranspl Immunol2003121 19 2814551029
   PubMed Web of Science ®Google Scholar
• DeckerMRothermundtCHollanderGTichelliARochlitzCRituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancyLancet Oncol200678 693 69416887487
   PubMed Web of Science ®Google Scholar
• FriedrichsBTiemannMSalwenderHVerpoortKWengerMKSchmitzNThe effects of rituximab treatment during pregnancy on a neonateHaematologica20069110 1426 142716963391
   PubMed Web of Science ®Google Scholar
• ChakravartyEFMurrayERKelmanAFarmerPPregnancy outcomes after maternal exposure to rituximabBlood20111175 1499 150621098742
   PubMed Web of Science ®Google Scholar
• OstensenMForgerFHow safe are anti-rheumatic drugs during pregnancy?Curr Opin Pharmacol2013133 470 47523522967
   PubMed Web of Science ®Google Scholar
• KlinkDTvan ElburgRMSchreursMWvan WellGTRituximab administration in third trimester of pregnancy suppresses neonatal B-cell developmentClin Dev Immunol20082008 27136318596903
   PubMedGoogle Scholar
• GualtierottiRIngegnoliFMeroniPLPre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et alClin Rheumatol2013325 727 72823636791
   PubMed Web of Science ®Google Scholar
• FlintJPanchalSHurrellABSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroidsRheumatology2016559 1693 169726750124
   PubMed Web of Science ®Google Scholar
• Gotestam SkorpenCHoeltzenbeinMTincaniAThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationAnn Rheum Dis2016755 795 81026888948
   PubMed Web of Science ®Google Scholar
• FriedmanMAWinthropKLVaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologistRheum Dis Clin North Am2017431 1 1327890167
   PubMed Web of Science ®Google Scholar
• RehnbergMBrisslertMAmuSZendjanchiKHawiGBokarewaMIVaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatmentArthritis Res Ther2010123 R11120529331
   PubMed Web of Science ®Google Scholar
• van AssenSHolvastABenneCAHumoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis Rheum2010621 75 8120039396
   PubMed Web of Science ®Google Scholar
• AradUTzadokSAmirSThe cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine2011298 1643 164821211590
   PubMed Web of Science ®Google Scholar
• OrenSMandelboimMBraun-MoscoviciYVaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral responseAnn Rheum Dis2008677 937 94117981914
   PubMed Web of Science ®Google Scholar
• Crnkic KapetanovicMSaxneTJonssonGTruedssonLGeborekPRituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritisArthritis Res Ther2013155 R17124286269
   PubMed Web of Science ®Google Scholar
• BinghamCO3rdLooneyRJDeodharAImmunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trialArthritis Rheum2010621 64 7420039397
   PubMed Web of Science ®Google Scholar
• GhrenassiaEMekinianARouagheSGanneNFainOReactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritisJoint Bone Spine2012791 100 10121944979
   PubMed Web of Science ®Google Scholar
• PyrpasopoulouADoumaSVassiliadisTChatzimichailidouSTriantafyllouAAslanidisSReactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritisRheumatol Int2011313 403 40419830433
   PubMed Web of Science ®Google Scholar
• EnnishiDYokoyamaMTeruiYDoes rituximab really induce hepatitis C virus reactivation?J Clin Oncol20082628 4695 4696 author reply 469618824720
   PubMed Web of Science ®Google Scholar
• BuchMHSmolenJSBetteridgeNUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnn Rheum Dis2011706 909 92021378402
   PubMed Web of Science ®Google Scholar
• ClavelGMoulignierASemeranoLProgressive multifocal leukoencephalopathy and rheumatoid arthritis treatmentsJoint Bone Spine Epub2017318
   PubMed Web of Science ®Google Scholar
• CasuloCMaraguliaJZelenetzADIncidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infectionsClin Lymphoma Myeloma Leuk2013132 106 11123276889
   PubMed Web of Science ®Google Scholar
• BreuerGSEhrenfeldMRosnerILate-onset neutropenia following rituximab treatment for rheumatologic conditionsClin Rheumatol2014339 1337 134024599679
   PubMed Web of Science ®Google Scholar